What is NPCE's market cap?

$457.89M, based on the Nov 4 close of $13.34.

Does Neuropace pay a dividend?

No regular cash dividend has been paid in the last year.

How much of NPCE is sold short?

886.2K shares, 3.7% of float, as of Oct 15, 2026.

What sector is NPCE in?

Healthcare, in the Surgical Instruments industry.

NASDAQ · NPCEHealthcareSurgical Instruments

Neuropace, Inc. Common Stock (NPCE)

$13.34+8.37%

Close Nov 4, 2026 · split-adjusted

Nov 3, 2026$12.46▲ 32.55% in range

Nov 3, 2025Low $9.40 · High $19.29Nov 3, 2026

What changed · written from our data

As of Nov 4, 2026

Neuropace closed at $13.34 on Nov 4, up 8.37%, 30.8% below its 52-week closing high. Volume of 228.6K shares was 2.18× its 20-day average (well above normal).

Split-adjusted performance: +5.3% over one month, -26.4% over six months, +41.9% over one year.

In the quarter ended Jun 30, 2026, revenue was $22.83M, up 17.1% from a year earlier, with a net margin of -27.2%.

Short interest was 886.2K shares at the Oct 15 settlement, down 1.9% from the prior report (3.7% of float, 8.3 days to cover).

Market cap$457.9M34.3M shares

Revenue · quarter$22.8M+17.1% YoY

Diluted EPS$-0.18—

P/E · TTM—P/S 4.6×

Net margin-27.2%Gross 82.8%

Dividend yieldNone

52-week range9.40 – 19.29−30.8% from high

Volume228.6K2.18× 20-day avg

Volatility · 60d43.5%Annualised

Short % of float3.7%8.3 days to cover

Net cash-$7.3MCash $51.7M

Next earnings—Not scheduled

Split-adjusted performance

1W +3.2%1M +5.3%3M −4.0%6M −26.4%YTD −13.6%1Y +41.9%3Y +100.9%5Y −13.3%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Surgical Instruments

Percentile among 110 companies (100 = best)

6-month momentum33

Revenue growth70

Net margin39

Value (low P/E)—

Size58

Industry medians: 6-month return −4.0%, revenue growth +8.9%, net margin −8.2%, P/E 30.5×.

Short interest

Details →

Shares short886.2K−1.9% vs prior

Days to cover8.3Settled Oct 15

% of float3.7%

Short vol. 10d45.6%of daily volume

Closest peers by size in Surgical Instruments

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
NPCENeuropace	$13.34	+8.37%	−26.4%	+17.1%	−27.2%	—	$457.9M
SSIISS Innovations International	$2.27	−2.58%	−44.2%	+39.4%	−19.1%	—	$455.1M	Compare
MDXGMiMedx Group	$3.20	−1.54%	−12.6%	−45.2%	−13.9%	—	$467.0M	Compare
CARLCarlsmed	$16.09	+11.74%	+63.5%	—	−55.5%	—	$439.3M	Compare
SIShoulder Innovations	$21.01	+6.00%	+63.0%	—	−59.1%	—	$437.4M	Compare
CERSCerus	$2.42	+3.21%	−6.8%	+6.3%	−0.9%	—	$486.7M	Compare
RCELAvita Medical	$16.32	+6.46%	+269.2%	+17.8%	−35.3%	—	$504.7M	Compare
DCTHDelcath Systems	$14.82	+2.92%	+31.6%	+20.6%	9.2%	966.6	$514.2M	Compare
ANGOAngioDynamics	$12.25	+4.43%	+10.9%	+6.9%	−8.8%	—	$515.2M	Compare

News about Neuropace

All news →

Why NeuroPace Stock Was Inching Higher on WednesdayThe Motley Fool · Mar 4, 2026▲ Positive

Quick answers

What does Neuropace do?: NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures.
What is NPCE's market cap?: $457.89M, based on the Nov 4 close of $13.34.
Does Neuropace pay a dividend?: No regular cash dividend has been paid in the last year.
How much of NPCE is sold short?: 886.2K shares, 3.7% of float, as of Oct 15, 2026.
What sector is NPCE in?: Healthcare, in the Surgical Instruments industry.

About Neuropace

NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.

HQ: Mountain View, CA220 employeesListed Apr 22, 2021neuropace.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology